1. Search Result
Search Result
Results for "

bezafibrate

" in MedChemExpress (MCE) Product Catalog:

10

Inhibitors & Agonists

5

Isotope-Labeled Compounds

Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-B0637
    Bezafibrate
    10+ Cited Publications

    BM15075

    PPAR Cardiovascular Disease Metabolic Disease
    Bezafibrate is an agonist of PPAR, with EC50s of 50 μM, 60 μM, 20 μM for human PPARα, PPARγ and PPARδ, and 90 μM, 55 μM, 110 μM for murine PPARα, PPARγ and PPARδ, respectively; Bezafibrate is used as an hypolipidemic agent.
    Bezafibrate
  • HY-W341625

    Endogenous Metabolite Neurological Disease Metabolic Disease Cancer
    Trihexosylceramide (d18:1/12:0) is a glycosphingolipid and mood-related compound. Trihexosylceramide (d18:1/12:0) is characterized by elevated serum levels in Mus musculus fed a high-fat diet, and its levels are positively correlated with mood Z-scores. Accumulation of Trihexosylceramide (d18:1/12:0) in tissues is considered the etiology of angiokeratoma corporis diffusum. Trihexosylceramide (d18:1/12:0) can be used in studies related to high-fat diet-induced mood disorders .\n


    Trihexosylceramide (d18:1/12:0)
  • HY-B0637S

    PPAR Cardiovascular Disease Metabolic Disease
    Bezafibrate-d6 is the deuterium labeled Bezafibrate. Bezafibrate is an agonist of PPAR, with EC50s of 50 μM, 60 μM, 20 μM for human PPARα, PPARγ and PPARδ, and 90 μM, 55 μM, 110 μM for murine PPARα, PPARγ and PPARδ, respectively; Bezafibrate is used as an hypolipidemic agent.
    Bezafibrate-d6
  • HY-146477S

    Isotope-Labeled Compounds Others
    Hydroxy Bezafibrate-d6 is the deuterium labeled Hydroxy Bezafibrate .
    Hydroxy Bezafibrate-d6
  • HY-B0637R

    BM15075 (Standard)

    Reference Standards PPAR Cardiovascular Disease Metabolic Disease
    Bezafibrate (Standard) is the analytical standard of Bezafibrate. This product is intended for research and analytical applications. Bezafibrate is an agonist of PPAR, with EC50s of 50 μM, 60 μM, 20 μM for human PPARα, PPARγ and PPARδ, and 90 μM, 55 μM, 110 μM for murine PPARα, PPARγ and PPARδ, respectively; Bezafibrate is used as an hypolipidemic agent.
    Bezafibrate (Standard)
  • HY-B0637S1

    BM15075-d4

    Isotope-Labeled Compounds PPAR Cardiovascular Disease Metabolic Disease
    Bezafibrate-d4 is deuterium labeled Bezafibrate. Bezafibrate is an agonist of PPAR, with EC50s of 50 μM, 60 μM, 20 μM for human PPARα, PPARγ and PPARδ, and 90 μM, 55 μM, 110 μM for murine PPARα, PPARγ and PPARδ, respectively; Bezafibrate is used as an hypolipidemic agent.
    Bezafibrate-d4
  • HY-W714951S

    Isotope-Labeled Compounds Others
    β-D-GlcUA-Bezafibrate-d6 is the deuterium labeled isotope of β-D-GlcUA-Bezafibrate.
    β-D-GlcUA-Bezafibrate-d6
  • HY-B0637S2

    BM15075-13C6

    Isotope-Labeled Compounds PPAR Cardiovascular Disease Metabolic Disease
    Bezafibrate- 13C6 (BM15075- 13C6) is 13C labeled Bezafibrate. Bezafibrate is an agonist of PPAR, with EC50s of 50 μM, 60 μM, 20 μM for human PPARα, PPARγ and PPARδ, and 90 μM, 55 μM, 110 μM for murine PPARα, PPARγ and PPARδ, respectively; Bezafibrate is used as an hypolipidemic agent.
    Bezafibrate-13C6
  • HY-106278A

    PPAR Metabolic Disease
    GW 590735 sodium is a potent and selective PPARα agonist with activity in regulating lipid metabolism. GW 590735 significantly increased high-density lipoprotein (HDL) cholesterol, decreased low-density lipoprotein (LDL) and very low-density lipoprotein (VLDL) cholesterol, and significantly reduced triglycerides. The maximum increases in HDL cholesterol for GW 590735 were 37%, 53% and 84%, respectively, compared with bezafibrate, torcetrapib and GW 590735 .
    GW 590735 sodium
  • HY-180181

    RAR/RXR Metabolic Disease Cancer
    RXR antagonist 6 (Compound 34) is a selective partial retinoid X receptor (RXR) antagonist. RXR antagonist 6 shows no agonistic activity for any of the human RXRα/β/γ subtypes but it can strongly inhibit the receptor activation induced by full agonists of RXR (such as Bezafibrate (HY-B0637)) with an IC50 of 2.7 μM. RXR antagonist 6 can enhance PMA (HY-18739)-induced THP-1 cell differentiation. RXR antagonist 6 can be used for the research of cancer, metabolic and neurological disease, such as lymphoma .
    RXR antagonist 6

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

 

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

 

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: